Researchers have developed a new approach to T cell therapy that is more effective in killing breast cancer cells. This new approach uses bispecific T cell engagers (BITEs) to redirect T cells to target and kill cancer cells. The researchers found that this approach was more effective than traditional T cell therapy and did not cause the same level of side effects. This is good news for patients with breast cancer, as it could lead to more effective and safer treatments.
Funding
This work was supported by the National Research Council of Thailand (NRCT) (grant number N41A640177).
Original Paper
Title of original paper: Anti-PD-L1 × anti-CD3 bispecific T-cell engager-armed T cells can overcome immunosuppression and redirect T cells to kill breast cancer cells expressing PD-L11
Journal: International Immunopharmacology
DOI: https://doi.org/10.1016/j.intimp.2023.111012
Correspondence
Piriya Luangwattananun (email: [email protected]),
Pa-thai Yenchitsomanus (email: [email protected], [email protected])